-
-
公开(公告)号：KR1020160006933A
公开(公告)日：2016-01-20
申请号：KR1020140086642
申请日：2014-07-10
Applicant: 한국과학기술연구원
Abstract: 본발명은인지장애질환검출용단백질다이머및 이의제조방법에관한것으로 P, S, L, S`, P`를포함하고, 상기 P의아미노산서열과 P`의아미노산서열이평행또는비평행하게배치되는입체구조를갖는하기 [화학식 1]로표시됨으로써, 평행또는비평행의입체구조에따른독성의차이및 다이머이상의올리고머구조에따른독성을알 수있으며인지장애질환을진단하는데이용할수 있는항체의개발에이용될수 있을뿐만아니라위의다이머를인식할수 있는물질의개발에이용가능하며, 이에는형광물질, 흡광물질, 발광물질, 핵의학등에이용할수 있는물질등도포함된다. 또한, 이를이용하여핵의학적뇌영상으로인지장애질환을진단할수 있는타겟물질을제조할수 있다. [화학식 1] P-S-L-S`-P`
Abstract translation: 本发明涉及一种用于检测认知障碍疾病的蛋白质二聚体及其制备方法。 蛋白二聚体包括P，S，L，S'和P'，并且由具有空间构象的化学式1表示，其中P的氨基酸序列和P ^'的氨基酸序列平行排列 或不并行。 根据二聚体或更多的二聚体结构的平行或非平行立体构象和毒性的毒性差异是已知的。 蛋白质二聚体可用于开发能够用于诊断认知障碍疾病的抗体，并且可用于开发能够识别二聚体的材料，其中该材料包括荧光材料，光吸收材料， 发光材料，能够用于核医学的材料等。 此外，可以制造能够通过使用其的核医学脑成像来诊断认知障碍疾病的靶材。
-
公开(公告)号：KR101418078B1
公开(公告)日：2014-07-10
申请号：KR1020130007540
申请日：2013-01-23
Applicant: 한국과학기술연구원
IPC: C07D215/12 , C07D401/06 , A61K31/47 , A61P25/00
CPC classification number: C07D215/06 , C07D215/20 , C07D401/06
Abstract: The present invention relates to a 2-(substituted ethynyl)quinoline derivative having activity as an mGluR5 antagonist and to a pharmaceutically acceptable salt of the same. The compound of the present invention can be used as a medicine to treat and prevent mGluR5 acceptor-mediated diseases, for example; Alzheimer′s, senile dementia, Parkinson′s disease, L-dopa-induced dyscinesia, Huntington′s chorea, amyotrophic lateral sclerosis, disseminated sclerosis, schizophrenia, anxiety disorders, dysthymia, neuropathic pains, drug dependence, fragile X syndrome, autism, migraine, and gastroesophageal reflux disease (GERD).
Abstract translation: 本发明涉及具有作为mGluR5拮抗剂的活性的2-（取代的乙炔基）喹啉衍生物及其药学上可接受的盐。 本发明的化合物可以用作治疗和预防mGluR5受体介导的疾病的药物; 老年痴呆症，老年痴呆症，帕金森病，左旋多巴诱发的运动障碍，亨廷顿氏舞蹈病，肌萎缩性侧索硬化，弥漫性硬化症，精神分裂症，焦虑障碍，心境恶劣，神经性疼痛，药物依赖，脆性X综合征，自闭症， 偏头痛和胃食管反流病（GERD）。
-
公开(公告)号：KR101362482B1
公开(公告)日：2014-02-12
申请号：KR1020120009756
申请日：2012-01-31
Applicant: 한국과학기술연구원
IPC: C07D471/04 , C07D217/04 , A61K31/4375 , A61P25/00
CPC classification number: C07D455/06 , C07F7/0812
Abstract: 본 발명은 테트라베나진 (TBZ)과 다이하이드로테트라베나진 (DTBZ)의 제조방법에 관한 것으로, 더욱 상세하게는 6,7-다이메톡시-1,2,3,4-테트라하이드로아이소퀴놀린과 4-메틸-2-(3-(트리메틸실릴)프로프-1-엔-2-일)펜탄을 출발물질로 사용하여, 알킬화 반응, 산화제 존재 하에서의 아자-프린스 고리화 반응, 산화반응을 순차적으로 수행하는 간결하고 짧은 반응공정에 의해 테트라베나진 (TBZ)과 다이하이드로테트라베나진 (DTBZ)을 제조하는 방법에 관한 것이다.
-
公开(公告)号：KR101351338B1
公开(公告)日：2014-01-14
申请号：KR1020110043180
申请日：2011-05-06
Applicant: 한국과학기술연구원
IPC: C07D403/12 , A61K31/496 , A61P25/00
Abstract: 본 발명은 칼슘 채널에 약학적 활성을 보이는 피라조일 피페라진 화합물 및 약제학적으로 허용 가능한 이의 염, 이들 화합물의 제조방법, 그리고 이들 화합물이 유효성분으로 함유된 약제조성물에 관한 것이다.
-
Patent Agency Ranking
公开(公告)号：KR101305434B1
公开(公告)日：2013-09-06
申请号：KR1020110014803
申请日：2011-02-18
Applicant: 한국과학기술연구원
IPC: C07D313/04 , C07D409/04 , C07D407/04
Abstract: 본 발명은 3,4-다이메틸렌옥세페인 화합물과 이의 제조방법에 관한 것으로서, 더욱 상세하게는 알렌닐 알코올 화합물과 알데하이드 화합물을 특정의 루이스산과 특정의 용매 존재하에서 프린스 고리화 반응을 수행하여 제조된, 입체선택성을 가지는 하기 화학식 1로 표시되는 3,4-다이메틸렌옥세페인 화합물과 이 화합물의 제조방법에 관한 것이다.
[화학식 1]
상기 화학식 1에서, R
1 은 수소원자; C
1-6 알킬기; 또는 페닐기를 나타내고, R
2 는 C
1-6 알킬기; 할로, 나이트로, C
1-6 알킬, 및 C
1-6 알콕시 중에서 선택된 1 내지 3개의 치환기로 치환 또는 비치환된 페닐기; 퓨란일기; 또는 티오펜일기를 나타낸다.-
37.发明授权
公开(公告)号：KR101264903B1
公开(公告)日：2013-05-15
申请号：KR1020100117602
申请日：2010-11-24
Applicant: 한국과학기술연구원
IPC: C07D413/10 , A61K31/422 , A61P31/04
CPC classification number: Y02A50/473 , Y02A50/481
Abstract: 본발명은항균활성을갖는신규한옥사졸리디논유도체또는이의약학적으로허용가능한염, 이들의제조방법, 및상기옥사졸리디논유도체또는이의약학적으로허용가능한염을유효성분으로포함하는항균조성물에관한것으로서, 본발명의옥사졸리디논유도체또는이의약학적으로허용가능한염은다양한내성균주를포함하는그람양성균에대하여우수한항균활성을나타낸다.
-
公开(公告)号：KR1020130010784A
公开(公告)日：2013-01-29
申请号：KR1020110071653
申请日：2011-07-19
Applicant: 한국과학기술연구원
IPC: C07D417/10 , C07D417/12 , C07D277/36 , A61K31/427
Abstract: PURPOSE: A methylidene-heterocyclic compound and a pharmaceutical composition containing the same are provided to strongly suppress IkappaB kinase-b(IKK-b) and to treat various inflammatory diseases. CONSTITUTION: A methylidene-heterocyclic compound is denoted by chemical formula 1. A pharmaceutical composition for preventing and treating inflammatory diseases contains the compound of chemical formula 1 as an active ingredient. The inflammatory diseases include rheumatoid arthritis, juvenile arthritis, asthma, spondyloarthopathies, gout, osteoarthritis, allergic rhinitis, atopic dermatitis, systemic lupuserythematosus, psoriasis, ulcerative colitis, SIRS, sepsis, or polymyositis. A method for preparing the compound of chemical formula 1 comprises: a step of cyclizing an aniline compound of chemical formula 2 and preparing a 3-phenyl rhodanine compound of chemical formula 3; and a step of condensing the compound of chemical formula 3 with aldehyde compound of R2-C(O)H under an acidic condition. [Reference numerals] (AA) Step 1; (BB) Step 2
Abstract translation: 目的：提供亚甲基杂环化合物和含有它们的药物组合物以强烈抑制IkappaB激酶b（IKK-b）并治疗各种炎性疾病。 构成：亚甲基杂环化合物由化学式1表示。用于预防和治疗炎性疾病的药物组合物含有化学式1的化合物作为活性成分。 炎性疾病包括类风湿性关节炎，青少年关节炎，哮喘，脊椎动物病痛，痛风，骨关节炎，过敏性鼻炎，特应性皮炎，系统性红斑狼疮，牛皮癣，溃疡性结肠炎，SIRS，败血症或多发性肌炎。 制备化学式1的化合物的方法包括：使化学式2的苯胺化合物环化并制备化学式3的3-苯基绕丹宁化合物的步骤; 和在酸性条件下将化学式3的化合物与R2-C（O）H的醛化合物缩合的步骤。 （附图标记）（AA）步骤1; （BB）步骤2
-
公开(公告)号：KR1020120097288A
公开(公告)日：2012-09-03
申请号：KR1020110016788
申请日：2011-02-24
Applicant: 한국과학기술연구원
IPC: C07D403/12 , C07D403/14 , A61K31/551 , A61P25/00
Abstract: PURPOSE: A pharmaceutical composition containing 1,4-diazepane pyrazole compound and a pharmaceutically acceptable salt thereof is provided to be used as an agent for preventing or treating brain diseases, heart diseases, cancer, epilepsy, and pain. CONSTITUTION: A 1,4-diazepane pyrazole compound is denoted by chemical formula 1. A pharmaceutical composition for preventing and treating brain diseases such as epilepsy, depression, Parkinson's diseases, dementia, sleep disorders, or heart diseases such as hypertension, cardiac arrhythmia, or myocardial infarction, or pain contains the compound of chemical formula 1 as an active ingredient. A method for preparing the compound of chemical formula 1 comprises a step of reacting pyrazolemethyl amine of chemical formula 2 with chloroacetyl chloride.
Abstract translation: 目的：提供含有1,4-二氮杂环庚烷吡唑化合物及其药学上可接受的盐的药物组合物，用作预防或治疗脑疾病，心脏病，癌症，癫痫和疼痛的药剂。 构成：1,4-二氮杂环庚烷吡唑化合物由化学式1表示。用于预防和治疗脑疾病如癫痫，抑郁症，帕金森病，痴呆，睡眠障碍或心脏病如高血压，心律失常， 或心肌梗塞，或疼痛含有化学式1的化合物作为活性成分。 制备化学式1的化合物的方法包括使化学式2的吡唑甲胺与氯乙酰氯反应的步骤。
-
公开(公告)号：KR1020120097287A
公开(公告)日：2012-09-03
申请号：KR1020110016787
申请日：2011-02-24
Applicant: 한국과학기술연구원
IPC: C07D401/12 , A61K31/454 , A61P25/00
Abstract: PURPOSE: A pharmaceutical composition containing pyrazoyl piperidine compounds and pharmaceutically acceptable salt thereof is provided to prevent or treat brain diseases, heard diseases, cancer, and pain. CONSTITUTION: A pyrazoyl piperidine compound is denoted by chemical formula 1. A pharmaceutical composition for treating cerebral diseases, cardiac diseases, cancer, or pain contains the compound of chemical formula 1 as an active ingredient. A method for preparing the compound comprises: a step of reacting piperidine acetate of chemical formula 2 and pyrazole methyl amine of chemical formula 3 of a step of reacting piperidine compound of chemical formula 4 with an aldehyde compound of chemical formula 5 by reduction-amination. [Reference numerals] (AA) Reductive amination
Abstract translation: 目的：提供含有吡唑基哌啶化合物及其药学上可接受的盐的药物组合物，以预防或治疗脑疾病，听到疾病，癌症和疼痛。 构成：化学式1表示吡唑基哌啶化合物。用于治疗脑疾病，心脏病，癌症或疼痛的药物组合物含有化学式1的化合物作为活性成分。 制备该化合物的方法包括：使化学式2的哌啶乙酸酯与化学式3的吡唑甲胺与化学式4的哌啶化合物与化学式5的醛化合物的还原胺化反应的步骤。 （参考号）（AA）还原胺化
-
-
-
-
-
-
-
-
-
Search Results
280
records
(took 0.037 seconds)
